Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Hematologic oncologist Eytan Stein (shown here with nurse practitioner Coleen Ranaghan) has led the development of several new drugs for acute myeloid leukemia. Acute myeloid leukemia (AML) is one of ...

Harry Erba, MD, PhD, professor of medicine at Duke Cancer Institute, chair of the SWOG Leukemia Committee, and co-chair of ...

ALL = Acute lymphoblastic leukemia; AML = Acute myeloid leukemia; FTI = Farnesyltransferase inhibitor; HDAC = Histone deacetylase; NF = Nuclear factor; Ph = Philadelphia chromosome; TKI = Tyrosine ...

Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for ...

The FDA has granted approval to revumenib for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia. 1 Data from the phase 1/2 AUGMENT-101 trial, as ...

Texas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States Texas A&M Drug Discovery Center and Department of Chemistry, Texas A&M ...

1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 2Louis V. Gerstner Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer ...